Siew-leng Melinda Teng

TL;DR: It is demonstrated that tumours expressing PD-L1-positive tumour-infiltrating immune cells had particularly high response rates, and patients with UBC, who are often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL3280A versus chemotherapy.

TL;DR: PD-L1 expression is prevalent in this disease and may protect cancer cells from immune-mediated degranulation, leading to a poor prognosis and limited treatment options.

TL;DR: PD-L1 may contribute to immune escape in UBC, a disease of high mutational complexity and immunogenicity and MPDL3280A was designed to restore T cell–mediated antitumor activity by restoring PD-L 1 activity.

TL;DR: MPDL3280A is a PD-L1-targeting antibody with an engineered Fc domain that disrupts PD- l1/PD-1 and PD- L1/B7.1 signaling that may inhibit immune-mediated antitumor responses in metastatic urothelial bladder cancer.

TL;DR: In this article, gene expression analyses of metastatic urothelial bladder cancer (UBC) patients were conducted to interrogate the tumor immune microenvironment in PD-L1-positive tumors and to identify potential mechanisms associated with response or resistance to MPDL3280A.